Our Work
Upcoming Events
Want to stay informed about important policy, market access, and health economics issues? Join us for our monthly sessions to learn more!
May
Navigating Market Access with Magnolia
Stay Tuned for More Information!
We would love to have you join our free, monthly educational series, “Navigating Market Access with Magnolia”!
Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
Decoding the 2025 Medicare Shifts: Key Insights for Pharma Market Access with Parker Edman
With the recent release of the 2025 Medicare plan enrollment data, pharma manufacturers must address significant shifts in the Part D prescription drug plan market, that could impact market access, formulary positioning, and patient affordability. We spoke with Parker Edman about the trends, challenges, and what manufacturers should prioritize to stay ahead.
-
Prescription Drug Affordability Boards: Considerations to Ensure Patient Access
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.
-
How The 340B Program Impacts Federal & State Tax Liability
While the 340B drug pricing program is often touted as cost-free to taxpayers, our analysis estimates the tax impact of the program for both self- and fully insured employees and workers across the US.
Market Access Briefs
A Blend of Core Concepts and Breaking Headlines
-
Prescription Drug Affordability Boards (PDABs)
What are PDABs? Prescription Drug Affordability Boards (PDABs) are state-appointed entities empowered to review drug prices, and, in some cases, set upper payment limits (UPLs) in an attempt to lower drug costs for identified populations within the state. The boards typically consist of five to nine members with expertise in healthcare economics, pharmacology, medicine, health…
-
Medicare Part D Changes for 2025
Direct Drug Price Negotiations and Inflation Rebates The Inflation Reduction Act (IRA) made several key changes to Part D. The Centers for Medicare and Medicaid Services (CMS) can now negotiate drug prices for certain high-priced/high-utilization medications. Additionally, drug companies are now required to pay CMS a rebate for Part D and B drugs if prices…
-
The Basics of Claims Data
What is Claims Data? Healthcare claims are submitted by providers to insurers for reimbursement. Nearly every encounter a patient has with the health care system generates a claim which, along with payment information, contains data on a patient’s diagnoses, procedures, and medications using standardized billing codes. This real-world data can be used for commercial targeting,…